Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2020-03-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
2019年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2019 年度内部控制评价报告' which translates to '2019 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2019. The content includes detailed descriptions of internal control scope, evaluation standards, defect classifications, and conclusions about the absence of major defects. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 4138 characters, which is relatively short but contains substantive evaluation content rather than just an announcement or certification. The nature of the report aligns with an Audit Report / Information (AR) category, as it deals with internal control evaluation and related regulatory requirements, not the full annual financial statements (10-K) or other categories. Therefore, the best classification is AR with high confidence. FY 2019
2020-03-30 Chinese
关于公司及子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase wealth management products. It includes detailed tables of purchases, balances, and returns of these financial products, risk disclosures, and risk control measures. The document is a specific update on financing activities related to the company's capital management, not a full financial report, earnings release, or regulatory certification. It does not contain comprehensive financial statements or management discussion of results, nor is it a notice of voting results or board changes. The content fits best under Capital/Financing Update (CAP) as it details the company's financing activities and capital usage related to wealth management products.
2020-01-22 Chinese
2019年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2019 annual performance forecast (业绩预告) from Jinling Pharmaceutical Co., Ltd. It provides estimated financial results for the full year 2019, including net profit and earnings per share, with explanations for the expected changes. It explicitly states that the forecast is unaudited and that the final audited results will be in the formal 2019 annual report. The document is short (1927 characters) and serves as a preliminary earnings forecast rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only, not a full annual report (10-K). FY 2019
2020-01-22 Chinese
关于提起诉讼的公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding the initiation of a lawsuit (civil litigation) related to a contract dispute. It details the parties involved, the background of the dispute, the legal claims, and the potential impact on the company's profits. There is no financial data, no report or presentation, and no mention of annual or interim reports. The document is a legal proceeding update and does not fit into financial report categories. Therefore, it best fits the category of Legal Proceedings Report (LTR). The document length is under 5,000 characters and contains substantive information about the lawsuit, not just a notice or certification, so it is not RPA or RNS.
2020-01-03 Chinese
第七届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at the 16th meeting of the 7th Supervisory Board of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting notice, date, voting results, and compliance with legal and regulatory requirements. There is no financial data, no mention of annual or interim reports, no audit information, and no indication of other report types. The document is a regulatory announcement about a board meeting decision, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2019-12-06 Chinese
关于所属控股子公司进行清算注销的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the liquidation and deregistration of a wholly owned subsidiary of the company. It includes details about the subsidiary, the board approval, and the impact on the company. There is no financial report or detailed financial statements presented, only summary information and board resolutions. The document is a formal announcement of a corporate action related to subsidiary liquidation, not a financial report, earnings release, or management discussion. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement about corporate structure changes without being a full management or board change announcement or a capital/financing update.
2019-12-06 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.